Corvus Pharmaceuticals (CRVS) Projected to Release Quarterly Earnings on Tuesday

Key Points

• Corvus Pharmaceuticals is expected to report Q3 2026 results after the market closes on Tuesday, November 3. Analysts forecast a quarterly loss of approximately $0.1921 per share, with the earnings call scheduled for 4:30 p.m. ET.
• The company reported a second-quarter loss of $0.19 per share, missing consensus expectations of a $0.16 loss. Analysts project full-year and next-year losses of $0.79 and $1.06 per share, respectively.
• CRVS has a consensus “Moderate Buy” rating and a $33.33 price target, though shares recently traded at $10.45 versus a 52-week range of $6.39 to $26.95. Corvus is developing soquelitinib, an immune-targeting therapy for T-cell malignancies.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) will likely be issuing its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect Corvus Pharmaceuticals to post earnings of ($0.1921) per share for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.03). On average, analysts expect Corvus Pharmaceuticals to post ($0.79) EPS for the current fiscal year and ($1.06) EPS for the next fiscal year.

Corvus Pharmaceuticals Stock Performance

Shares of CRVS opened at $10.45 on Tuesday. Corvus Pharmaceuticals has a fifty-two week low of $6.39 and a fifty-two week high of $26.95. The firm has a 50 day moving average price of $12.31 and a 200-day moving average price of $14.28.

Analyst Upgrades and Downgrades

CRVS has been the subject of a number of recent research reports. Cantor Fitzgerald reissued an "overweight" rating on shares of Corvus Pharmaceuticals in a research note on Wednesday, September 16th. LADENBURG THALM/SH SH raised Corvus Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, July 30th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Corvus Pharmaceuticals in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $33.33.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that harness the immune system to treat cancer. The company's research centers on therapies designed to modulate immune-cell activity and address diseases with significant unmet medical needs.

Corvus' leading product candidate is soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of inducible T-cell kinase (ITK). The company is studying soquelitinib as a potential treatment for T-cell malignancies, including peripheral T-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.